Tests iparomlimab/tuvonralimab with chemoradiotherapy in locally advanced cervical cancer
Tests an immunotherapy drug with chemoradiotherapy in adults with locally advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with locally advanced cervical cancer that has spread to nearby lymph nodes but not to distant organs. It tests the drug Iparomlimab/Tuvonralimab together with chemoradiotherapy.
- Age
- 18 to 75 years
- Sex
- Women only
- Disease stage
- HPV-related cervical squamous cell, adenocarcinoma or adenosquamous cancer, FIGO 2018 stage T3a-4a (III-IVA), N1, M0, with at least one disease site that can be measured (RECIST 1.1).
- Earlier treatment
- Cannot have had immune checkpoint inhibitors or other cancer immunotherapy before. Cannot have had a total hysterectomy.
- Biomarker or test result
- HPV-related cervical cancer is required. ECOG performance status of 0 or 1.
Main reasons for not taking part
- Other types of cervical cancer, such as neuroendocrine carcinoma or sarcoma
- Cancer that has spread to distant parts of the body
- Prior total hysterectomy
- Unable or unwilling to receive brachytherapy
- Prior immune checkpoint inhibitor or other cancer immunotherapy
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07232654, who can take part
Where in China
- National Cancer Center/Cancer HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Trial code
- NCT07232654
- Record updated
- 1 December 2025
- Original description
This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.Read full original descriptionShow less
A Clinical Study to Evaluate the Safety and Efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer
This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
Inclusion: Informed consent; Female patients aged ≥18 years and ≤ 75 years at time of inform consent signature; Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Expected survival ≥ 3 months; Patients must have histologically confirmed diagnosis of HPV-related cervical squamous, or adenocarcinoma, or adenosquamous carcinoma; FIGO 2018 stage T3a-4a (III-IVA), N1 (positive lymph node metastasis on CT/MRI with short-axis ≥1 cm, or PET-CT showing one or more lymph node metastases with SUVmax ≥2.5), M0; Has at least one evaluable disease per RECIST 1.1; Has adequate organ function; Hematology: ANC ≥1.5 ×10⁹/L; platelets ≥100 ×10⁹/L; hemoglobin ≥90 g/L (no blood transfusion or growth factor support within 7 days); Renal: CrCl ≥50 mL/min (Cockcroft-Gault formula), urine protein <2+ or 24h <1.0 g; Hepatic: Total bilirubin ≤1.5×ULN; AST and ALT ≤2.5×ULN; Coagulation: INR and APTT ≤1.5×ULN; Cardiac: LVEF ≥50%; Women of childbearing potential: a negative urine or serum pregnancy test within 3 days prior to the first dose of study drug (if the urine pregnancy test result cannot be confirmed as negative, a serum pregnancy test must be performed, and the serum result will be considered definitive).If a female participant of childbearing potential engages in sexual activity with a male partner who is not surgically sterile, she must use an acceptable method of contraception starting from screening and agree to continue using the same contraception for 120 days after the last dose of study drug. Whether to discontinue contraception after this period should be discussed with the investigator; Willingness to comply with the study procedures before study entry; Main Exclusion Criteria:; Cervical cancer of other histology (e.g., neuroendocrine carcinoma, sarcoma); Evidence of distant metastasis; Prior total hysterectomy (subtotal or cervical-sparing surgery allowed); Unable or unwilling to receive brachytherapy; Prior treatment with immune checkpoint inhibitors or other tumor immunotherapy; Systemic corticosteroid (>10 mg/day prednisone or equivalent) or immunosuppressive therapy within 2 weeks (exceptions: inhaled/topical ≤10 mg/day, physiologic replacement ≤10 mg/day, premedication for hypersensitivity); Immunomodulatory drugs within 2 weeks (e.g., thymosin, interferons, IL-2).